Skip to main content
AKBLF logo

ALK-Abelló A/S (AKBLF) Stock Price & Analysis

ALK-Abelló A/S (AKBLF) — price $36.50 (0.00%), as of the Nov 19, 2026 trading session; market cap $8.10B.

Educational signal · not a buy or sell recommendation · How to read this

$36.50 $0.00 (0.00%) Market Cap $8.10B

ALK-Abelló A/S · AKBLF

ALK-Abelló A/S is a leading allergy solutions company specializing in immunotherapy products for various allergies. The company operates globally, offering a range of treatments and diagnostic products to address the growing need for allergy management.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • PTGX · Protagonist Therapeutics, Inc. · 88 /100
  • CORT · Corcept Therapeutics Incorporated · 91 /100
  • KNSA · Kiniksa Pharmaceuticals, Ltd. · 98 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$36.50
Change on the day0.00%
Market capitalisation$8.10B—
Price / earnings (trailing)38.86
Shares traded on the day100

Price & events

Other perspectives

Council score for ALK-Abelló A/S (AKBLF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Moderate
Debt/Equity Strong
ROE Strong
Gross Margin Strong

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is ALK-Abelló A/S (AKBLF), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. ALK-Abelló A/S (AKBLF) is the company analyzed here. It employs 2,613 people. In Q2 FY2026 it reported revenue of kr1.79B and net income of kr338M. The market values it at $8.10B.

2 · Latest results

What do the latest results show for ALK-Abelló A/S (AKBLF)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of kr1.79B. Against analyst estimates the company has EPS beat 4 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026kr1.79Bkr338Mkr1.50 (diluted)
Q1 FY2026kr1.77Bkr437Mkr1.95 (diluted)
Q4 FY2025kr1.73Bkr265Mkr1.21 (diluted)
Q3 FY2025kr1.53Bkr314Mkr1.40 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for ALK-Abelló A/S (AKBLF)?

Short answer · as of

The distress and quality screens read Altman Z 12.69 · Piotroski F 7. Trailing ratios: ROE 20.8% · ROA 13.9% · current ratio 3.46 · earnings yield 2.5% · free-cash-flow yield 3.4%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held AKBLF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported AKBLF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about ALK-Abelló A/S (AKBLF)?

Read these with our analysis →

Common Questions About AKBLF

These answers are editorial: 1 of these 8 answers is drawn from the AKBLF research dossier (written Jun 13, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is AKBLF a good stock to buy?

Stock Expert AI does not rate AKBLF buy, sell or hold. ALK-Abelló A/S has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the AKBLF stock price today?

The last price recorded for ALK-Abelló A/S (AKBLF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What does ALK-Abelló A/S do?

ALK-Abelló A/S specializes in developing and manufacturing allergy immunotherapy products. The company offers a range of treatments, including injections, sublingual drops, and tablets, targeting various allergens such as house dust mites, grasses, and trees.

What are the key factors to evaluate for AKBLF?

Evaluate AKBLF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Strategic Partnerships and Collaborations: ALK-Abelló is exploring strategic partnerships with healthcare providers and research institutions to enhance its product offerings and market reach. Not financial advice.

How frequently does AKBLF data refresh on this page?

AKBLF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven AKBLF's recent stock price performance?

ALK-Abelló A/S (AKBLF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established leader in allergy immunotherapy with a strong market presence. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider AKBLF overvalued or undervalued right now?

The trailing P/E of ALK-Abelló A/S (AKBLF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research AKBLF before investing?

Before investing in ALK-Abelló A/S (AKBLF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 13, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 13 figures on this page — 9 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.